Focusing on critical illness, Mindray Biotech and Likang Biomedical have reached a strategic cooperation
March 7, 2025
Source: drugdu
43
The reporter learned from Mindray Biotech that Mindray Biotech and Likang Biomedical Technology Holdings Co., Ltd. recently officially signed a strategic cooperation agreement. This strategic cooperation focuses on blood gas products and focuses on the field of critical and emergency diseases for adults and neonates. It is the advantage of Wuhan Mindray and Likang Biotech in forming strategic synergy and resource complementarity in three aspects: expert guidance, benchmark demonstration and market expansion. Innovate instant diagnosis and lead smart medical care.
https://finance.eastmoney.com/a/202503043335621969.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Zhao Jing, Vice Chairman of Buchang Pharmaceutical, made suggestions on AI empowering traditional Chinese medicine at the two sessions March 7, 2025
- It is recommended to optimize the review and approval mechanism of biomedicine in Chengdu and Chongqing, and further promote the collection of non-immunization program vaccines March 7, 2025
- It is recommended to optimize the construction of the centralized procurement system for biopharmaceuticals and support the high-quality development of enterprises March 7, 2025
- Breakthrough in Nobel Prize level base modification technology, Aibo Bio freeze-dried mRNA vaccine approved for clinical use | Yingke Family March 6, 2025
- Single product sells over 1 billion in China, hidden leader lays off 10% of employees March 6, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
